Data and Methods for Evaluating the Impact of Opioid Formulations with Properties Designed to Deter Abuse in the Postmarket SettingFDA Docket No. FDA-2017-N-2903
Evaluation of the Extended Release and Long-Acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS)FDA Docket No. FDA-2016-N-0820
